Breaking Health News: Investment Moves, Drug Updates and Disease Outbreaks

This summary covers recent health events including investment in German firm Gerresheimer, updates on the U.S. Medicare drug list, Illumina's launch of gene sequencers, Baxter's IV supply restoration, FTC legal actions, and new authorizations and settlements from Novavax and GSK. Additionally, reports include Roche’s cancer drug trials and California's bird flu cases.


Devdiscourse News Desk | Updated: 10-10-2024 02:28 IST | Created: 10-10-2024 02:28 IST
Breaking Health News: Investment Moves, Drug Updates and Disease Outbreaks
This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

In a striking twist for German medical packaging maker Gerresheimer, shares soared nearly 6.8% on news that activist investor Ricky Sandler acquired a 5.43% stake. As markets responded, shares maintained a 4% increase on Wednesday post-disclosure.

The U.S. government has revealed a preliminary listing of 101 generic drugs capped at $2 for Medicare enrollees. This move marks a substantial step in reducing prescription costs, covering commonly used medications like penicillin and metformin.

Tech advancements continue as Illumina launches cost-effective gene sequencing devices, aiming to broaden access for research labs. Meanwhile, California confirms a third human bird flu case, raising concerns amid ongoing disease monitoring.

(With inputs from agencies.)

Give Feedback